Imad Moustafa, hair transplant specialist
Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Testing after a year catches any developing issues before they become problematic
Figure 19: Photograph of frozen intestinal starting material being handled by Jan Wiberg (left) and Johnny Sderlund (right) in Mutt's laboratory, photographer unknown
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Results: GLP-1RAs attenuate inflammation by suppressing NF-B and p38 MAPK pathways, reduce oxidative stress, enhance insulin sensitivity, and promote mitochondrial and endothelial stability